



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/734,583
Applicant : ANDOU et al.
Filed : December 15, 2003
TC/A.U. : 3738
Examiner : Not Yet Assigned

Docket No. : 2923-595
Customer No. : 06449
Confirmation No. : 2600


SUBMISSION OF PRIORITY APPLICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Submitted herewith is a certified copy of European Patent Application No. 99115613.4 filed August 6, 1999 and Japanese Patent Nos. JP 8/355812 filed December 25, 1996 and JP 10/141379 May 22, 1998, from which priority has been claimed in the above-referenced patent application.

Respectfully submitted,

By 
Steven M. Giovannetti
Attorney for Applicants
Registration No. 51,739
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040



THIS PAGE BLANK (USPTO)



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99115613.4

**CERTIFIED COPY OF
PRIORITY DOCUMENT**

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

24/08/00

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°: 99115613.4

Anmeldetag:
Date of filing:
Date de dépôt: 06/08/99

Anmelder:
Applicant(s):
Demandeur(s):
HyGene AG, c/o Mäder + Baumgartner Treuhand AG
8121 Neuhausen am Rheinfall
SWITZERLAND

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Monomeric protein of the TGF-beta family

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
C12N15/12, C07K14/495, A61K38/18

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

PATENTANWÄLTE

European Patent Attorneys
European Trade Mark Attorneys

DIPL.-ING. H. WEICKMANN
DIPL.-ING. F. A. WEICKMANN
DIPL.-CHEM. B. HUBER
DR.-ING. H. LISKA
DIPL.-PHYS. DR. J. PRECHTEL
DIPL.-CHEM. DR. B. BÖHM
DIPL.-CHEM. DR. W. WEISS
DIPL.-PHYS. DR. J. TIESMEYER
DIPL.-PHYS. DR. M. HERZOG
DIPL.-PHYS. B. RUTTENSPERGER

POSTFACH 860 820
81635 MÜNCHEN

KOPERNIKUSSTRASSE 9
81679 MÜNCHEN

TELEFON (089) 45563 0

TELEX 522 621

TELEFAX (089) 45563 999

E-MAIL email@weickmann.de

Unser Zeichen:

20780P EP/BBcl

Anmelder:

HyGene AG

c/o Mäder + Baumgartner

Treuhand AG

Schwanenfelsstrasse 10a

8121 Neuhausen am Rheinfall

Schweiz

EPO - Munich
52

06. Aug. 1999

Monomeric Protein of the TGF- β Family

- 1 -

EPO-Munich
52

06. Aug. 1999

Monomeric Protein of the TGF- β Family**Description**

5

The present invention concerns a biologically active protein from the TGF- β superfamily, wherein this protein remains in monomeric form due to substitution or deletion of a cysteine which is responsible for the dimerization in the wild-type protein. Further the invention concerns a nucleic acid, which codes for a protein according to the invention, an expression vector
10 containing such nucleic acid and a host cell, containing a corresponding nucleic acid or an expression vector, said nucleic acid being suitable for the expression of the protein. The invention also concerns a pharmaceutical composition containing the protein according to the invention or a nucleic
15 acid coding therefor. The use of the pharmaceutical composition according to the invention concerns the prevention or treatment of all conditions which can also be treated with the dimeric form of the corresponding protein.

20

Many growth factors from the TGF- β superfamily (Kingsley, Genes and Development 8, 133-146 (1994) as well as the references cited therein) are relevant for a wide range of medical treatment methods and applications which in particular concern promotion of cell proliferation and tissue formation, including wound healing and tissue reproduction. Such growth
25 factors in particular comprise members of the TGF- β (transforming growth factor, cf. e.g. Roberts and Sporn, Handbook of Experimental Pharmacology 95 (1990), page 419-472, editors: Sporn and Roberts), the DVR-group (Hötten et al., Biochem. Biophys. Res. Comm. 206 (1995), page 608-613 and further literature cited therein) including BMPs (bone morphogenetic protein, cf. e.g. Rosen and Thies, Growth Factors in Perinatal Development
30 (1993), page 39-58, editors: Tsang, Lemons and Balistreri) and GDFs (growth differentiation factors), the inhibin/activin (cf. e.g. Vale et al., The

- 2 -

Physiology of Reproduction, second edition (1994), page 1861-1878, editors: Knobil and Neill) and the GDNF protein family (Rosenthal, Neuron 22 (1999), page 201-203; Airaksinen et al. Mol Cell Neurosci 13 (1999), page 313-325). Although the members of the TGF- β superfamily show high
5 amino acid homologies in the mature part of the protein, in particular 7 conserved cysteines, they show considerable variations in their exact functions. Often individual growth factors of these families exhibit a plurality of functions at the same time, so that their application is of interest in various medical indications. Some of these multifunctional proteins also
10 have survival promoting effects on neurons in addition to functions such as e.g. regulation of the proliferation and differentiation in many cell types (Roberts and Sporn, supra; Sakurai et al., J. Biol. Chem. 269 (1994), page 14118-14122). Thus e.g. trophic effects on embryonic motoric and sensory neurons were demonstrated for TGF- β in vitro (Martinou et al., Devl. Brain
15 Res. 52, page 175-181 (1990) and Chalazonitis et al., Dev. Biol. 152, page 121-132 (1992)). In addition, effects promoting survival are shown for dopaminergic neurons of the mid-brain for the proteins TGF- β -1, -2, -3, activin A and GDNF (glial cell line-derived neurotrophic factor), a protein which has structural similarities to TGF- β superfamily members, these
20 effects being not mediated via astrocytes (Kriegstein et al., EMBO J. 14, page 736-742 (1995)).

Interesting members of the TGF- β superfamily or active variants thereof comprise the TGF- β proteins like TGF- β 1, TGF- β 2, TGF- β 3, TGF- β 4, TGF- β 5
25 (U.S. 5,284,763; EP 0376785; U.S. 4,886,747; DNA 7 (1988), page 1-8), EMBO J. 7 (1988), page 3737-3743), Mol. Endo. 2 (1988), page 1186-1195), J. Biol. Chem. 265 (1990), page 1089-1093), OP1, OP2 and OP3 proteins (U.S. 5,011,691, U.S. 5,652,337, WO 91/05802) as well as BMP2, BMP3, BMP4 (WO 88/00205, U.S. 5,013,649 and WO 89/10409,
30 Science 242 (1988), page 1528-1534), BMP5, BMP6 and BMP-7 (OP1) (Proc. Natl. Acad. Sci. 87 (1990), page 9841-9847, WO 90/11366), BMP8 (OP2) (WO 91/18098), BMP9 (WO 93/00432), BMP10 (WO 94/26893),

- 3 -

BMP11 (WO 94/26892), BMP12 (WO 95/16035), BMP13 (WO95/16035), BMP15 (WO 96/36710), BMP16 (WO 98/12322), BMP3b (Biochem. Biophys. Res. Comm. 219 (1996), page 656-662), GDF1 (WO 92/00382 and Proc. Natl. Acad. Sci. 88 (1991), page 4250-4254), GDF8 (WO 5 94/21681), GDF10 (WO95/10539), GDF11 (WO 96/01845), GDF5 (CDMP1, MP52) (WO 95/04819; WO96/01316; WO 94/15949, WO 96/14335 and WO 93/16099 and Nature 368 (1994), page 639-643), GDF6 (CDMP2, BMP13) (WO 95/01801, WO 96/14335 and WO95/16035), GDF7 (CDMP3, BMP12) (WO 95/01802 and WO 95/10635), GDF14 (WO 10 97/36926), GDF15 (WO 99/06445), GDF16 (WO 99/06556), 60A (Proc. Natl. Acad. Sci. 88 (1991), page 9214-9218), DPP (Nature 325 (1987), page 81-84), Vgr-1 (Proc. Natl. Acad. Sci. 86 (1989), page 4554-4558) Vg-1, (Cell 51 (1987), page 861-867), dorsalin (Cell 73 (1993), page 687-702), MIS (Cell 45 (1986), page 685-698), pCL13 (WO 97/00958), 15 BIP (WO 94/01557), inhibin α , activin β A and activin β B (EP 0222491), activin β C (MP121) (WO 96/01316), activin β E and GDF12 (WO 96/02559 and WO 98/22492), activin β D (Biochem. Biophys. Res. Comm. 210 (1995), page 581-588), GDNF (Science 260 (1993), page 1130-1132, WO 93/06116), Neurturin (Nature 384 (1996), page 467-470), Persephin 20 (Neuron 20 (1998), page 245-253, WO 97/33911), Artemin (Neuron 21 (1998), page 1291-1302), Mic-1 (Proc. Natl. Acad. Sci USA 94 (1997), page 11514-11519), Univin (Dev. Biol. 166 (1994), page 149-158), ADMP (Development 121 (1995), page 4293-4301), Nodal (Nature 361 (1993), page 543-547), Screw (Genes Dev. 8 (1994), page 2588-2601). Other 25 useful proteins include biologically active biosynthetic constructs including biosynthetic proteins designed using sequences from two or more known morphogenetic proteins. Examples of biosynthetic constructs are disclosed in U.S. 5,011,691 (e.g. COP-1, COP-3, COP-4, COP-5, COP-7 and COP-16). The disclosure of the cited publications including patents or patent 30 applications are incorporated herein by reference.

- 4 -

The occurrence of proteins of the TGF- β superfamily in various tissuous stages and development stages corresponds with differences with regard to their exact functions as well as target sites, life span, requirements for auxiliary factors, necessary cellular physiological environment and/or resistance to degradation.

The proteins of the TGF- β superfamily exist as homodimers or heterodimers having a single disulfide bond. This disulfide bond is mediated by a specific and in most of the proteins conserved cysteine residue of the respective monomers. Up to now it was considered as indispensable for the biological activity that the protein is present in its dimeric form. Several publications indicated that biological activity can only be obtained for dimeric proteins and it was speculated that this dimer formation is important for further polymer formation of two or more dimers to achieve intercellular signal transmission by simultaneous binding to type I and type II receptors for the TGF- β superfamily proteins on cells. It was assumed that only this simultaneous binding to both kinds of receptors would allow for effective intercellular signal transmission for the benefit of the patient (Bone, volume 19 (1996), page 569-574).

A disadvantage of the use of these proteins as medicaments and their production is, that they are not readily obtainable in biologically active and sufficiently pure form by recombinant expression in prokaryots without intensive renaturation procedures.

Thus it was the object of the present invention to provide a simple and inexpensive possibility to reproducibly produce proteins exhibiting high biological activity, wherein this biological activity should essentially correspond to that of the dimers of the proteins of said families.

This object is solved according to the invention by a protein selected from the members of the TGF- β protein superfamily, such protein being

- 5 -

necessarily monomeric due to substitution or deletion of a cysteine which is responsible for dimeric formation.

Surprisingly it has been found that the substitution or deletion of the cysteine, which normally effects the dimerization in the proteins, results upon expression and correct folding (proper formation of the intramolecular disulfide bridges) in a monomeric protein that retains the biological activity of the dimeric form. Even more surprisingly, it was found that at least some of the monomeric proteins show a higher activity, based on the weight of protein, than their respective dimeric forms. Apart from this improved biological activity an important advantage for the proteins according to the invention is that they can be expressed in a large amount in prokaryotic hosts and upon simple refolding of the monomers they are obtained in high purity and very high yield without the need to separate dimerized from non-dimerized (monomeric) protein. The findings of the present invention are very surprising since, as already mentioned above, it was common understanding that only a dimer of the morphogenetic proteins has biological activity. Despite this understanding the proteins according to the invention show an up to two-fold higher activity than that of the dimer on the basis of protein weight. The smaller size of the proteins of the invention, while maintaining the biological activity, can also be considered as advantageous, e.g. for applications concerning the brain since the monomeric protein can much easier pass the blood-brain-barrier than the dimeric form.

The proteins according to the invention encompass all proteins of the mentioned protein families that are normally present in dimeric form. Also parts of such proteins that retain substantial activity or fusion proteins or precursor forms of proteins shall be considered as encompassed by the present invention as well as biologically active naturally occurring or biosynthetic variants of TGF- β superfamily proteins, as long as they show at least considerable biological activity.

- 6 -

In a preferred embodiment of the present invention the monomeric protein is a mature protein or a biologically active part or variant thereof. The term "biologically active part or variant thereof" is meant to define either fragments retaining activity, precursor proteins that are e.g. cleaved at the site of activity to the mature form or show biological activity themselves, or also variants that still maintain essentially the biological activity of the wild-type protein. Such variants preferably contain conservative amino acid substitutions, but especially at the N-terminal part of the mature proteins even considerable deletions or substitutions do not lead to a considerable loss of biological activity. It is well within the skill of the man in the art to determine whether a certain protein shows the required biological activity. Proteins showing at least 70% and preferably at least 80% homology to the mature wild-type proteins of the above referenced protein families should be understood as encompassed by the present invention, as long as they contain the deletion or substitution of a cysteine, as required for the proteins according the invention, and therefore do not form dimers.

It is especially preferred that proteins according to the invention contain at least the 7 cysteine region characteristic for the TGF- β protein superfamily.

This specific 7 cysteine region is considered to be the most important part of the proteins in view of the biological activity. Therefore proteins retaining this critical region are preferred proteins according to the invention. It is disclosed in the state of the art which cysteine is responsible in a certain protein family or protein for dimer formation (see for example: Schlunegger & Grutter (1992) Nature 358, 430-434; Daopin et al., (1992) Science 257, 369-373 and Griffith et al., Proc. Natl. Acad. Sci. 93 (1996), page 878-883). This cysteine has to be deleted or substituted by another amino acid to form a protein according to the invention.

The 7 cysteine region is known for many proteins of the TGF- β protein superfamily. In this region the respective location of the cysteine residues

- 7 -

to each other is important and is only allowed to vary slightly in order not to lose the biological activity. Consensus sequences for such proteins are known in the state of the art and all proteins complying with such consensus sequences are considered to be encompassed by the present invention.

In an especially preferred embodiment of the present invention the protein contains a consensus sequence according to the following sequence

$C(Y)_{25-29} C Y Y Y C(Y)_{25-35} X C(Y)_{27-34} C Y C$ (Formula I),

wherein C denotes cysteine, Y denotes any amino acid including cysteine and X denotes any amino acid except cysteine.

More preferably the protein according to the invention contains a consensus sequence according to the following sequence

$C(Y)_{28} C Y Y Y C(Y)_{30-32} X C(Y)_{31} C Y C$ (Formula II),

wherein C, X and Y have the same meaning as defined above.

Even more preferably the protein according to the invention contains a consensus sequence according to the following sequence

$C(X)_{28} C X X X C(X)_{31-33} C(X)_{31} C X C$ (Formula III),

wherein C and X have the same meaning as defined above.

In these consensus sequences especially preferred distances between the respective cysteine residues are contained, wherein also already the dimer forming cysteine is substituted by another amino acid. As with all proteins of said protein superfamily the location of and distance between the cysteines is more important than the identity of the other amino acids contained in this region. Therefore, the consensus sequence shows the respective location of the cysteines, but does not show the identity of the

- 8 -

other amino acids, since these other amino acids are widely variable in the proteins of the TGF- β protein superfamily.

5 In a preferred embodiment of the present invention the monomeric protein according to the invention is a morphogenetic protein.

Most of the members of the TGF- β protein superfamily are morphogenetic proteins that are useful for treatments where regulation of differentiation and proliferation of cells or progenitor cells is of interest. This can result in
10 replacement of damaged and/or diseased tissue like for example skeletal (bone, cartilage) tissue, connective tissue, periodontal or dental tissue, neural tissue, tissue of the sensory system, liver, pancreas, cardiac, blood vessel and renal tissue, uterine or thyroid tissue etc. Morphogenetic proteins are often useful for the treatment of ulcerative or inflammatory
15 tissue damage and wound healing of any kind such as enhanced healing of ulcers, burns, injuries or skin grafts. Especially preferred proteins according to the invention belong to the TGF- β , BMP, GDF, activin or GDNF families. Several BMP proteins which were originally discovered by their ability to induce bone formation, have been described, as also indicated above.
20 Meanwhile, several additional functions have been found as it is also true for members of the GDFs. These proteins show a very broad field of applications and especially are in addition to their bone and cartilage growth promoting activity (see for example: WO 88/00205, WO 90/11366, WO 91/05802) useful in periodontal disease, for inhibiting periodontal and tooth
25 tissue loss, for sealing tooth cavities, for enhancing integration of a tooth in a tooth socket (see for example: WO 96/26737, WO 94/06399, WO 95/24210), for connective tissue such as tendon or ligament (see for example: WO 95/16035), for improving survival of neural cells, for inducing growth of neural cells and repairing neural defects, for damaged CNS tissue
30 due to stroke or trauma (see for example: WO 97/34626, WO 94/03200, WO 95/05846), for maintaining or restoring sensory perception (see for example WO 98/20890, WO 98/20889), for renal failure (see for example:

- 9 -

WO 97/41880, WO 97/41881), for liver regeneration (see for example WO 94/06449), for regeneration of myocardium (see for example WO 98/27995), for treatment or preservation of tissues or cells for organ or tissue transplantation, for integrity of gastrointestinal lining (see for example
5 WO 94/06420), for increasing progenitor cell population as for example hematopoietic progenitor cells by ex vivo stimulation (see for example WO 92/15323), etc. One preferred member of the GDF family is the protein MP52 which is also termed GDF-5 or CDMP-1. Applications for MP52 reflect several of the already described applications for the BMP/GDF family.
10 MP52 is considered to be a very effective promoter of bone and cartilage formation as well as connective tissue formation (see for example WO 95/04819, Hötten et al., (1996), Growth Factors 13, 65-74, Storm et al., (1994) Nature 368, 639-643, Chang et al., (1994) J. Biol. Chem. 269 (45), 28227-28234). In this connection MP52 is useful for applications
15 concerning the joints between skeletal elements (see for example Storm & Kingsley (1996) Development 122, 3969-3979). One example for connective tissue is tendon and ligament (Wolfman et al., (1997), J. Clin. Invest. 100, 321-330, Aspenberg & Forslund (1999), Acta Orthop Scand 70, 51-54, WO 95/16035). MP52 is also useful for tooth (dental and
20 periodontal) applications (see for example WO 95/04819, WO 93/16099, Morotome et al. (1998), Biochem Biophys Res Comm 244, 85-90). MP52 is useful in wound repair of any kind. It is in addition very useful for promoting tissue growth in the neuronal system and survival of dopaminergic neurons, for example. MP52 in this connection is useful for
25 applications in neurodegenerative diseases like e.g. Parkinson's disease and possibly also Alzheimer's disease for Huntington chorea tissues (see for example WO 97/03188, Krieglstein et al., (1995) J. Neurosci Res. 42, 724-732, Sullivan et al., (1997) Neurosci Lett 233, 73-76, Sullivan et al. (1998), Eur. J. Neurosci 10, 3681-3688). MP52 allows to maintain nervous
30 function or to retain nervous function in already damaged tissues. MP52 is therefore considered to be a generally applicable neurotrophic factor. It is also useful for diseases of the eye, in particular retina cornea and optic

- 10 -

nerve (see for example WO 97/03188, You et al. (1999), Invest Ophthalmol Vis Sci 40, 296-311). The monomeric MP52 is expected to show all the already described activities of the dimeric form as well as some further described activities as described for the dimeric BMP/GDF family members.

5 It is expected to be for example also useful for increasing progenitor cell populations and for stimulating differentiation of progenitor cells ex vivo. Progenitor cells can be cells which take part in the cartilage formation process or hematopoietic progenitor cells. It is also useful for damaged or diseased tissue where a stimulation of angiogenesis is advantageous (see
10 for example: Yamashita et al. (1997), Exp Cell Res 235, 218-226).

An especially preferred protein according to the invention therefore is protein MP52 or a biologically active part or variant thereof. Like in the already above mentioned definition of these terms MP52 can e.g. be used
15 in its mature form, however, it can also be used as a fragment thereof at least containing the 7 cysteine region or also in a precursory form. Deviations at the N-terminal part of mature MP52 do not affect its activity to a considerable degree. Therefore, substitutions, deletions or additions on the N-terminal part of the proteins are still within the scope of the present
20 invention. It might be useful to add a peptide to the N-terminal part of the protein, e.g. for purification reasons. It might not be necessary to cleave off this added peptide after expression and purification of the protein. Additional peptides at the N- or C-terminal part of the protein may also serve for the targeting of the protein to special tissues such as nerve or
25 bone tissue or for the penetration of the blood/brain barrier. Generally, also fusion proteins of a monomeric protein according to the invention and another peptide or group are considered within the scope of the present invention, wherein these other peptides or groups are directing the localization of the fusion protein, e.g. because of an affinity to a certain
30 tissue type etc. Examples for such fusion proteins are described in WO 97/23612. The protein containing such addition will retain its biological

- 11 -

activity at least as long as such addition does not impair the formation of the biologically active conformation of the protein.

5 In an especially preferred embodiment of the present invention the proteins comprises the amino acid sequence according to SEQ.ID.NO.1 (DNA and protein sequence) and SEQ.ID.No.2 (protein sequence, only), respectively. SEQ.ID.NO.2 shows the complete protein sequence of the prepro protein of human MP52, as already disclosed in WO 95/04819. The start of the mature protein lies preferably in the area of amino acids 352-400, especially
10 preferred at amino acids 381 or 382. Therefore, the mature protein comprises amino acids 381-501 or 382-501. The first alanine of the mature protein can be deleted and the mature protein then preferably comprises amino acids 383-501. The cysteine at position 465 that is present in the already described dimeric MP52 protein is according to the invention either
15 deleted or substituted by another amino acid. This deletion or substitution is represented by Xaa at the respective position in SEQ.ID.Nos.1 and 2.

The activin/inhibin family proteins are of interest for applications related to contraception, fertility and pregnancy (see for example WO 94/19455, U.S.
20 5,102,868). They are also of interest for applications like repair or prevention of diseases of the nervous system, they can be used in the repair of organ tissue such as liver and even in bone and cartilage, too. In this connection MP121 (activin β C) is especially useful in applications for growth or regeneration of damaged and/or diseased tissue, especially the
25 liver tissue, neural tissue, skeletal tissue (see for example WO 96/01316, WO 98/22492 and WO 97/03188). MP121 is known to be predominantly expressed in the liver whereby the mRNA is markedly reduced after partial hepatectomy. MP121 is expected to regulate the liver mass (Zhang et al., Endocrine Journal 44 (1997), page 759-764). The monomeric MP121
30 shows all the already described activities of the dimeric form as well as some further described activities as described for the dimeric TGF- β superfamily members. It is for example also expected to be useful in

- 12 -

treatment of ulceration (for example stomach ulceration) and useful for integrity of gastrointestinal lining and for stimulating differentiation of progenitor cells ex vivo, treatment or preservation of mammalian tissue or cells, e.g. for organ or tissue transplantation.

5

A further preferred protein according to the invention therefore is MP121, a member of the activin/inhibin protein family. Also for this protein a biologically active part or variant thereof is encompassed by the present invention according to the above defined rules. An especially preferred
10 embodiment is shown in SEQ.ID.NO.3 (DNA and protein sequence) and SEQ.ID.NO.4 (protein sequence, only) respectively. SEQ.ID.NO.4 shows the complete amino acid sequence of the prepro protein of human MP121, that has already been disclosed in WO 96/01316. The start of the mature protein lies preferably between amino acids 217 and 247, most preferred
15 at amino acid 237. A preferred mature protein therefore comprises the mature part of the protein starting at amino acid 237 and ending at amino acid 352. However, also the precursor protein comprising the whole shown amino acid sequence is encompassed by the present invention. The cysteine at position 316 is according to the invention either deleted or substituted
20 by another amino acid, being represented by Xaa in SEQ.ID.Nos.3 and 4.

The amino acid by which the cysteine residue effecting the dimerization is substituted can be selected by any amino acid that does not impair the formation of a biologically active conformation. The amino acid is preferably
25 selected from the group of alanine, serine, threonine, leucine, isoleucine, glycine and valine.

The proteins according to the invention are in summary characterized by the absence of the cysteine residue in the amino acid sequence responsible for
30 the dimer formation. This absence can be effected by substitution of this cysteine by another amino acid or by deletion. In case of deletion, however, it must be assured for the protein that the formation of the biologically

- 13 -

active conformation is not hindered. The same is true for the selection of the substitution amino acid, wherein it is preferred to use an amino acid which has a form similar to cysteine.

5 The monomeric proteins according to the invention can be easily produced, in particular by expression in prokaryots and renaturation according to known methods. It is advantageous that the protein can be obtained in exceedingly biologically active form. The proteins exhibit in monomeric form about the same activity as the dimer so that based on the amount of active
10 substance only half of the monomeric protein has to be used in order to obtain the same positive biological effects.

A further subject matter of the present invention is a nucleic acid encoding a protein according to the invention. It is obvious that the nucleic acid has
15 to have such a sequence that a deletion or substitution of the cysteine responsible for the dimer formation is achieved. The nucleic acid can be a naturally occurring nucleic acid, but also a recombinantly produced or processed nucleic acid. The nucleic acid can be both a DNA sequence and an RNA sequence, as long as the protein according to the invention can be
20 obtained from this nucleic acid upon expression in a suitable system.

In a preferred embodiment of the invention the nucleic acid is a DNA sequence. This DNA sequence in an especially preferred embodiment of the invention comprises a sequence as shown in SEQ.ID.NO.1 and
25 SEQ.ID.NO.3, respectively, or parts thereof. SEQ.ID.NO.1 shows a nucleic acid encoding MP52, wherein the codon for the cysteine responsible for the dimer formation is replaced by another codon which does not encode cysteine or deleted. This substitution or deletion is shown as "nnn" in the sequence protocols. SEQ.ID.NO.3 shows a nucleic acid encoding MP121,
30 wherein also the codon for the cysteine effecting the dimer formation is replaced by a respective different codon or deleted. Instead of the complete

- 14 -

sequences of SEQ.ID.NOs.1 or 3 also parts can be used that encode the mature proteins or fragments also described above.

It is preferred in the framework of the present invention that the nucleic acid apart from the coding sequences also contains expression control sequences. Such expression control sequences are known to the man skilled in the art and serve to control the expression of the encoded protein in a host cell. The host cell does not have to be an isolated cell, moreover, the nucleic acid can be expressed in the patient in vivo in the target tissue.

This can be done by inserting the nucleic acid into the cell genome, however, it is also possible to transform host cells with expression vectors containing a nucleic acid according to the invention. Such expression vectors are a further subject matter of the present invention, wherein the nucleic acid is inserted in a suitable vector system, the vector system being selected according to the desired expression of the protein. The vector system can be a eukaryotic vector system, but - in the framework of the present invention - it is preferably a prokaryotic vector system, with which the proteins can be produced in prokaryotic host cells in a particularly easy and pure manner. In addition, the expression vector can be a viral vector.

Also host cells in turn are a further subject matter of the present invention. The host cells are characterized in that they contain a nucleic acid according to the invention or an expression vector according to the invention and that they are able to use the information present in the nucleic acids and in the expression vector, respectively, for the expression of a monomeric protein according to the invention.

Although in the framework of the present invention also eukaryotic host cells are suitable for the production of the protein, it is, as mentioned already several times above, particularly advantageous that the protein according to the invention can be produced in prokaryotic host cells, which therefore represent a preferred embodiment of the present invention.

- 15 -

After such preferred expression in prokaryotic host cells the protein is purified and renatured according to known methods, thereby effecting intramolecular cystine bridge formation.

5 Since, however, not only in vitro production of the monomeric protein is possible, but also in vivo expression of a nucleic acid according to the invention, a further preferred embodiment is a eukaryotic host cell, and especially a eukaryotic host cell containing the DNA in its genome, or as an expression vector. Such host cell can also be useful for application to an
10 individual in need of morphogenic treatment.

Further subject matters of the present application are pharmaceutical compositions comprising at least one monomeric protein according to the invention or at least one nucleic acid encoding for such a protein or at least
15 one corresponding expression vector, or at least one eukaryotic host cell expressing the monomeric protein.

The protein itself, but also a nucleic acid according to the invention, an expression vector or a host cell can be considered to be advantageous as
20 active substances in a pharmaceutical composition. Also combinations of monomeric proteins, with either biological activities in the same or different applications, can be used in preferred pharmaceutical compositions. Especially preferred for neuronal applications are combinations of MP52 with other TGF- β superfamily proteins, both in monomeric form, like for
25 example with GDNF (see WO 97/03188). Also preferred for neuronal applications are combinations of TGF- β with GDNF, both in monomeric form. Also for applications concerning cartilage and/or bone the combination of several monomeric proteins might be useful, like MP52 with
30 a protein of TGF- β (see e.g. WO 92/09697) or MP52 with a cartilage maintenance-inducing protein such as BMP-9 (see e.g. WO 96/39170). When a nucleic acid or an expression vector is used, however, it has to be ensured that when administering to the patient there has to be an

- 16 -

environment in which the nucleic acid and the expression vector, respectively, can be expressed and the protein according to the invention can be produced in vivo at the site of action. The same applies accordingly to the host cell according to the invention. When using expression vectors
5 or host cells it is also possible that they encode more than one monomeric protein of the invention to produce a combination of two or more monomeric proteins.

It is advantageous to both the protein and the nucleic acid or the expression
10 vector or the host cell when they are applied in and/or on a biocompatible matrix. The matrix material can be transplanted into the patient, e.g. surgically, wherein the protein either is effective on the surface of the matrix material or the protein or the DNA encoding the protein can be slowly released from the matrix material and then be effective over a long
15 period of time. Additionally it is possible and advantageous to use a biodegradable matrix material in the pharmaceutical composition, wherein this material preferably dissolves during the protein induced tissue formation so that a protein or a nucleic acid contained therein is released and the newly formed tissue replaces the matrix material.

20 Finally, in case of applications relating to bone formation, it is advantageous to use a matrix material which is itself e.g. osteogenically active. By using such a matrix material it becomes possible to achieve a synergistic effect of protein and matrix material and to effect a particularly rapid and effective
25 bone formation.

An especially preferred matrix material that can be used according to the invention is a matrix material as described in U.S. 5,231,169 and U.S. 5,776,193 and especially for applications like spinal fusion.

30 When using a combination of a matrix material and protein and/or nucleic acid and/or expression vector, it is preferable to sterilize such a combination

- 17 -

prior to its use. The matrix and the morphogenetic protein can be separately sterilized and then combined, but it is preferred to terminally sterilize the device consisting of matrix and morphogenetic protein. Terminal sterilization can be achieved by ionizing radiation as already described for dimeric proteins (U.S. 5,674,292) but it is also advantageous to use ethylene oxide.

Of course this invention also comprises pharmaceutical compositions containing further substances like e.g. pharmacologically acceptable auxiliary and carrier substances. However, the protein according to the invention, also in case a matrix material is used, does not necessarily have to be used together with this matrix material, but can also be administered systemically, wherein it concentrates preferably in the surrounding of an implanted matrix material.

For some applications the protein according to the invention and the nucleic acid forming this protein, respectively or the expression vector or host cell can preferably be present in an injectable composition. Implants are not necessary or possible for every form of application of the proteins according to the invention. However, it is also possible to provide an implantable vessel or an implantable micropump containing for example semipermeable membranes in which the protein according to the invention or the nucleic acid generating it is contained, from which either one is slowly released over a prolonged period of time. The pharmaceutical composition according to the invention can also contain other vehicles which make it possible that the proteins or the nucleic acids or the expression vectors encoding these proteins be transported to the site of activity and released there, wherein e.g. liposomes or nanospheres can be used. In principle, it is also possible to apply host cells, like e.g. implanted embryonic cells expressing the proteins. Cells transfected with recombinant DNA may be encapsulated prior to implantation. Any other practicable but herein not explicitly described form of application of the pharmaceutical composition according to the invention and their corresponding manufacture are also comprised by the

- 18 -

present invention, as long as they contain a protein according to the invention or a nucleic acid or an expression vector coding therefor, or a host cell expressing it.

5 Although the indications shall not be restricted herein and all indications exhibiting the dimeric form of the protein according to the invention are also comprised, in the following types of application for the compositions according to the invention are listed which are considered to be particularly preferred indications for the proteins of the present invention. On the one
10 hand, there is the prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease, or generally situations, in which cartilage and/or bone formation is desirable or for spinal fusion, and on the other hand, there is prevention or therapy of damaged or diseased tissue associated with connective tissue including
15 tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue including CNS tissue and neuropathological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue
20 regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal lining, for treatment of
25 disturbances in fertility, contraception or pregnancy.

Diseases concerning sensory organs like the eye are also to be included in the preferred indication of the pharmaceutical composition according to the invention. As neuronal diseases again Parkinson's and Alzheimer's diseases
30 can be mentioned as examples.

- 19 -

The pharmaceutical compositions according to the invention can be used in any desired way, the pharmaceutical compositions are formulated preferably for surgical local application, topical or systemic application. Auxiliary substances for the individual application form can of course be present in the pharmaceutical composition according to the invention. For some applications it can be advantageous to add some further substances to the pharmaceutical composition as for example Vitamin D (WO 92/21365), parathyroid hormone related peptide (WO 97/35607), chordin (WO 98/21335), anti-fibrinolytic agent (EP 535091), anti-metabolites (WO 95/09004), alkyl cellulose (WO 93/00050), mannitol (WO 98/33514), sugar, glycine, glutamic acid hydrochloride (U.S. 5,385,887), antibiotics, antiseptics, amino acids and/or additives which improve the solubility or stability of the monomeric morphogenetic protein as for example nonionic detergents (e.g. Tween 80), basic amino acids, carrier proteins (e.g. serum albumin), full length propeptides of the TGF- β superfamily or parts thereof.

As can be already gathered from the description of proteins, nucleic acids and pharmaceutical compositions, the proteins according to the invention and respective nucleic acids, which provide for an expression of the proteins at the site of activity, can advantageously be applied in all areas for which also the dimeric forms of the proteins, as described, can be applied. In the framework of the present invention therefore a further subject matter is the use of a pharmaceutical composition according to the present invention for the treatment or prevention of any indications of the dimeric forms of the proteins according to the invention.

Herein it is again possible to conduct surgical operations and to implant the pharmaceutical composition (in particular contained on a matrix material), an administration in liquid or otherwise suitable form via, e.g. injection or oral administration seems to be as suitable as a topical application for e.g. tissue regeneration.

- 20 -

Fig. 1A shows a two dimensional graph of the conformation of recombinantly produced dimeric MP52 with the deleted first alanine. In this figure the 7 cysteine bridges contained in a dimer are shown, wherein there are 3 intramolecular cystine bridges per monomer unit and 1 intermolecular cystine bridge connecting both monomers. Fig. 1B shows the monomeric protein according to the invention wherein the cysteine of the amino acid sequence of MP52 has been replaced by X that denotes any amino acid except cysteine.

5

THIS PAGE BLANK (USPTO)

- 21 -

SEQUENCE LISTING

5 <110> HyGene AG

<120> Monomeric Protein of the TGF-beta Family

<130> 20780PEP Monomeric TGF-beta protein

10 <140>

<141>

<160> 4

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 2703

20 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

25 <222> (640)..(2142)

<400> 1

ccatggcctc gaaagggcag cgggtgatttt ttccacataa atatatcgca cttaaagtga 60

30 tttagacagc atgacatcag agagtaatta aattggtttg ggttggaatt ccgtttccaa 120

ttcctgagtt caggtttgta aaagatTTTT ctgagcacct gcaggcctgt gagtgtgtgt 180

35 gtgtgtgtgt gtgtgtgtgt gtgtgtgtga agtattttca ctggaaagga ttcaaaaacta 240

gggggaaaaa aaaactggag cacacaggca gcattacgcc attcttcctt cttggaaaaa 300

tccctcagcc ttatacaagc ctccttcaag ccctcagtcg gttgtgcagg agaaaggggg 360

- 22 -

cggttggtt tctcctttca agaacgagtt attttcagct gctgactgga gacgggtgcac 420
 gtctggatac gagagcattt ccactatggg actggataca aacacacacc cggcagactt 480
 5 caagagtctc agactgagga gaaagccttt cctttctgctg ctactgctgc tgccgctgct 540
 10 tttgaaagtc cactcctttc atgggtttttc ctgccaaacc agaggcacct ttgctgctgc 600
 cgctgttctc tttggtgtca ttcagcggct ggccagagg atg aga ctc ccc aaa 654
 15 Met Arg Leu Pro Lys
 1 5
 ctc ctc act ttc ttg ctt tgg tac ctg gct tgg ctg gac ctg gaa ttc 702
 20 Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp Leu Asp Leu Glu Phe
 10 15 20
 atc tgc act gtg ttg ggt gcc cct gac ttg ggc cag aga ccc cag ggg 750
 25 Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly Gln Arg Pro Gln Gly
 25 30 35
 acc agg cca gga ttg gcc aaa gca gag gcc aag gag agg ccc ccc ctg 798
 30 Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys Glu Arg Pro Pro Leu
 40 45 50
 gcc cgg aac gtc ttc agg cca ggg ggt cac agc tat ggt ggg ggg gcc 846
 35 Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser Tyr Gly Gly Gly Ala
 55 60 65
 acc aat gcc aat gcc agg gca aag gga ggc acc ggg cag aca gga ggc 894
 40 Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr Gly Gln Thr Gly Gly
 70 75 80 85
 ctg aca cag ccc aag aag gat gaa ccc aaa aag ctg ccc ccc aga ccg 942
 45 Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys Leu Pro Pro Arg Pro

- 23 -

	90	95	100	
	ggc ggc cct gaa ccc aag cca gga cac cct ccc caa aca agg cag gct			990
5	Gly Gly Pro Glu Pro Lys Pro Gly His Pro Pro Gln Thr Arg Gln Ala			
	105	110	115	
	aca gcc cgg act gtg acc cca aaa gga cag ctt ccc gga ggc aag gca			1038
10	Thr Ala Arg Thr Val Thr Pro Lys Gly Gln Leu Pro Gly Gly Lys Ala			
	120	125	130	
	ccc cca aaa gca gga tct gtc ccc agc tcc ttc ctg ctg aag aag gcc			1086
15	Pro Pro Lys Ala Gly Ser Val Pro Ser Ser Phe Leu Leu Lys Lys Ala			
	135	140	145	
	agg gag ccc ggg ccc cca cga gag ccc aag gag ccg ttt cgc cca ccc			1134
20	Arg Glu Pro Gly Pro Pro Arg Glu Pro Lys Glu Pro Phe Arg Pro Pro			
	150	155	160	165
	ccc atc aca ccc cac gag tac atg ctc tcg ctg tac agg acg ctg tcc			1182
25	Pro Ile Thr Pro His Glu Tyr Met Leu Ser Leu Tyr Arg Thr Leu Ser			
	170	175	180	
	gat gct gac aga aag gga ggc aac agc agc gtg aag ttg gag gct ggc			1230
30	Asp Ala Asp Arg Lys Gly Gly Asn Ser Ser Val Lys Leu Glu Ala Gly			
	185	190	195	
	ctg gcc aac acc atc acc agc ttt att gac aaa ggg caa gat gac cga			1278
35	Leu Ala Asn Thr Ile Thr Ser Phe Ile Asp Lys Gly Gln Asp Asp Arg			
	200	205	210	
	ggt ccc gtg gtc agg aag cag agg tac gtg ttt gac att agt gcc ctg			1326
40	Gly Pro Val Val Arg Lys Gln Arg Tyr Val Phe Asp Ile Ser Ala Leu			
	215	220	225	
	gag aag gat ggg ctg ctg ggg gcc gag ctg cgg atc ttg cgg aag aag			1374
45	Glu Lys Asp Gly Leu Leu Gly Ala Glu Leu Arg Ile Leu Arg Lys Lys			

- 24 -

	230	235	240	245													
	ccc	tcg	gac	acg	gcc	aag	cca	gcg	gcc	ccc	gga	ggc	ggg	cgg	gct	gcc	1422
5	Pro	Ser	Asp	Thr	Ala	Lys	Pro	Ala	Ala	Pro	Gly	Gly	Gly	Arg	Ala	Ala	
					250					255					260		
	cag	ctg	aag	ctg	tcc	agc	tgc	ccc	agc	ggc	cgg	cag	cgg	gcc	tcc	ttg	1470
10	Gln	Leu	Lys	Leu	Ser	Ser	Cys	Pro	Ser	Gly	Arg	Gln	Pro	Ala	Ser	Leu	
					265					270					275		
	ctg	gat	gtg	cgc	tcc	gtg	cca	ggc	ctg	gac	gga	tct	ggc	tgg	gag	gtg	1518
15	Leu	Asp	Val	Arg	Ser	Val	Pro	Gly	Leu	Asp	Gly	Ser	Gly	Trp	Glu	Val	
			280						285					290			
	ttc	gac	atc	tgg	aag	ctc	ttc	cga	aac	ttt	aag	aac	tcg	gcc	cag	ctg	1566
20	Phe	Asp	Ile	Trp	Lys	Leu	Phe	Arg	Asn	Phe	Lys	Asn	Ser	Ala	Gln	Leu	
			295					300					305				
	tgc	ctg	gag	ctg	gag	gcc	tgg	gaa	cgg	ggc	agg	gcc	gtg	gac	ctc	cgt	1614
25	Cys	Leu	Glu	Leu	Glu	Ala	Trp	Glu	Arg	Gly	Arg	Ala	Val	Asp	Leu	Arg	
		310				315				320				325			
	ggc	ctg	ggc	ttc	gac	cgc	gcc	gcc	cgg	cag	gtc	cac	gag	aag	gcc	ctg	1662
30	Gly	Leu	Gly	Phe	Asp	Arg	Ala	Ala	Arg	Gln	Val	His	Glu	Lys	Ala	Leu	
					330					335				340			
	ttc	ctg	gtg	ttt	ggc	cgc	acc	aag	aaa	cgg	gac	ctg	ttc	ttt	aat	gag	1710
35	Phe	Leu	Val	Phe	Gly	Arg	Thr	Lys	Lys	Arg	Asp	Leu	Phe	Phe	Asn	Glu	
			345						350					355			
	att	aag	gcc	cgc	tct	ggc	cag	gac	gat	aag	acc	gtg	tat	gag	tac	ctg	1758
40	Ile	Lys	Ala	Arg	Ser	Gly	Gln	Asp	Asp	Lys	Thr	Val	Tyr	Glu	Tyr	Leu	
			360					365					370				
	ttc	agc	cag	cgg	cga	aaa	cgg	cgg	gcc	cca	ctg	gcc	act	cgc	cag	ggc	1806
45	Phe	Ser	Gln	Arg	Arg	Lys	Arg	Arg	Ala	Pro	Leu	Ala	Thr	Arg	Gln	Gly	

- 25 -

375 380 385
 aag cga ccc agc aag aac ctt aag gct cgc tgc agt cgg aag gca ctg 1854
 5 Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys Ser Arg Lys Ala Leu
 390 395 400 405
 cat gtc aac ttc aag gac atg ggc tgg gac gac tgg atc atc gca ccc 1902
 10 His Val Asn Phe Lys Asp Met Gly Trp Asp Asp Trp Ile Ile Ala Pro
 410 415 420
 ctt gag tac gag gct ttc cac tgc gag ggg ctg tgc gag ttc cca ttg 1950
 15 Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu Cys Glu Phe Pro Leu
 425 430 435
 cgc tcc cac ctg gag ccc acg aat cat gca gtc atc cag acc ctg atg 1998
 20 Arg Ser His Leu Glu Pro Thr Asn His Ala Val Ile Gln Thr Leu Met
 440 445 450
 aac tcc atg gac ccc gag tcc aca cca ccc acc nnn tgt gtg ccc acg 2046
 25 Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr Xaa Cys Val Pro Thr
 455 460 465
 cgg ctg agt ccc atc agc atc ctc ttc att gac tct gcc aac aac gtg 2094
 30 Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp Ser Ala Asn Asn Val
 470 475 480 485
 gtg tat aag cag tat gag gac atg gtc gtg gag tgc tgt ggc tgc agg 2142
 35 Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu Ser Cys Gly Cys Arg
 490 495 500
 tagcagcact ggccctctgt ctctctgggt ggcacatccc aagagcccct tctgcactc 2202
 40 ctggaatcac agaggggtca ggaagctgtg gcaggagcat ctacacagct tgggtgaaag 2262
 gggattccaa taagcttgct cgctctctga gtgtgacttg ggctaaaggc ccccttttat 2322
 45

- 26 -

ccacaagttc ccttggtga ggattgctgc cgtctgctg atgtgaccag tggcaggcac 2382

aggtccaggg agacagactc tgaatgggac tgagtcccag gaaacagtgc tttccgatga 2442

5

gactcagccc accattttctc ctcacctggg ccttctcagc ctctggactc tcctaagcac 2502

10 ctctcaggag agccacaggt gccactgcct cctcaaatca catttggtgcc tggtgacttc 2562

ctgtccctgg gacagttgag aagctgactg ggcaagagtg ggagagaaga ggagagggct 2622

15

tggatagagt tgaggagtgt gaggctgtta gactgttaga tttaaagtga tattgatgag 2682

ataaaaagca aaactgtgcc t

2703

20

<210> 2

<211> 501

25

<212> PRT

<213> Homo sapiens

<400> 2

Met Arg Leu Pro Lys Leu Leu Thr Phe Leu Leu Trp Tyr Leu Ala Trp

30

1

5

10

15

Leu Asp Leu Glu Phe Ile Cys Thr Val Leu Gly Ala Pro Asp Leu Gly

20

25

30

35

Gln Arg Pro Gln Gly Thr Arg Pro Gly Leu Ala Lys Ala Glu Ala Lys

35

40

45

Glu Arg Pro Pro Leu Ala Arg Asn Val Phe Arg Pro Gly Gly His Ser

50

55

60

40

Tyr Gly Gly Gly Ala Thr Asn Ala Asn Ala Arg Ala Lys Gly Gly Thr

65

70

75

80

Gly Gln Thr Gly Gly Leu Thr Gln Pro Lys Lys Asp Glu Pro Lys Lys

45

85

90

95

- 27 -

	Leu	Pro	Pro	Arg	Pro	Gly	Gly	Pro	Glu	Pro	Lys	Pro	Gly	His	Pro	Pro	
				100					105					110			
5	Gln	Thr	Arg	Gln	Ala	Thr	Ala	Arg	Thr	Val	Thr	Pro	Lys	Gly	Gln	Leu	
			115					120					125				
	Pro	Gly	Gly	Lys	Ala	Pro	Pro	Lys	Ala	Gly	Ser	Val	Pro	Ser	Ser	Phe	
		130					135					140					
10	Leu	Leu	Lys	Lys	Ala	Arg	Glu	Pro	Gly	Pro	Pro	Arg	Glu	Pro	Lys	Glu	
	145					150					155					160	
	Pro	Phe	Arg	Pro	Pro	Pro	Ile	Thr	Pro	His	Glu	Tyr	Met	Leu	Ser	Leu	
				165						170					175		
15	Tyr	Arg	Thr	Leu	Ser	Asp	Ala	Asp	Arg	Lys	Gly	Gly	Asn	Ser	Ser	Val	
			180					185					190				
	Lys	Leu	Glu	Ala	Gly	Leu	Ala	Asn	Thr	Ile	Thr	Ser	Phe	Ile	Asp	Lys	
20		195						200					205				
	Gly	Gln	Asp	Asp	Arg	Gly	Pro	Val	Val	Arg	Lys	Gln	Arg	Tyr	Val	Phe	
		210					215					220					
25	Asp	Ile	Ser	Ala	Leu	Glu	Lys	Asp	Gly	Leu	Leu	Gly	Ala	Glu	Leu	Arg	
	225				230					235						240	
	Ile	Leu	Arg	Lys	Lys	Pro	Ser	Asp	Thr	Ala	Lys	Pro	Ala	Ala	Pro	Gly	
				245					250						255		
30	Gly	Gly	Arg	Ala	Ala	Gln	Leu	Lys	Leu	Ser	Ser	Cys	Pro	Ser	Gly	Arg	
			260					265					270				
	Gln	Pro	Ala	Ser	Leu	Leu	Asp	Val	Arg	Ser	Val	Pro	Gly	Leu	Asp	Gly	
35		275					280						285				
	Ser	Gly	Trp	Glu	Val	Phe	Asp	Ile	Trp	Lys	Leu	Phe	Arg	Asn	Phe	Lys	
		290				295						300					
40	Asn	Ser	Ala	Gln	Leu	Cys	Leu	Glu	Leu	Glu	Ala	Trp	Glu	Arg	Gly	Arg	
	305				310					315						320	
	Ala	Val	Asp	Leu	Arg	Gly	Leu	Gly	Phe	Asp	Arg	Ala	Ala	Arg	Gln	Val	
				325				330							335		
45																	

- 28 -

His Glu Lys Ala Leu Phe Leu Val Phe Gly Arg Thr Lys Lys Arg Asp
 340 345 350

Leu Phe Phe Asn Glu Ile Lys Ala Arg Ser Gly Gln Asp Asp Lys Thr
 5 355 360 365

Val Tyr Glu Tyr Leu Phe Ser Gln Arg Arg Lys Arg Arg Ala Pro Leu
 370 375 380

10 Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala Arg Cys
 385 390 395 400

Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp Asp Asp
 405 410 415

15 Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu Gly Leu
 420 425 430

20 Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala Val
 435 440 445

Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro Pro Thr
 450 455 460

25 Xaa Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe Ile Asp
 465 470 475 480

Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val Val Glu
 485 490 495

30 Ser Cys Gly Cys Arg
 500

35
 <210> 3
 <211> 2272
 <212> DNA
 <213> Homo sapiens

40
 <220>
 <221> CDS
 <222> (128) .. (1183)

45 <400> 3

- 29 -

caaggagcca tgccagctgg acacacactt cttccagggc ctctggcagc caggacagag 60

ttgagaccac agctgttgag accctgagcc ctgagtctgt attgctcaag aagggccttc 120

5

cccagca atg acc tcc tca ttg ctt ctg gcc ttt ctc ctc ctg gct cca 169

Met Thr Ser Ser Leu Leu Leu Ala Phe Leu Leu Leu Ala Pro

10

1

5

10

acc aca gtg gcc act ccc .aga gct ggc ggt cag tgt cca gca tgt ggg 217

Thr Thr Val Ala Thr Pro Arg Ala Gly Gly Gln Cys Pro Ala Cys Gly

15

15

20

25

30

ggg ccc acc ttg gaa ctg gag agc cag cgg gag ctg ctt ctt gat ctg 265

Gly Pro Thr Leu Glu Leu Glu Ser Gln Arg Glu Leu Leu Leu Asp Leu

20

35

40

45

gcc aag aga agc atc ttg gac aag ctg cac ctc acc cag cgc cca aca 313

Ala Lys Arg Ser Ile Leu Asp Lys Leu His Leu Thr Gln Arg Pro Thr

25

50

55

60

ctg aac cgc cct gtg tcc aga gct gct ttg agg act gca ctg cag cac 361

Leu Asn Arg Pro Val Ser Arg Ala Ala Leu Arg Thr Ala Leu Gln His

30

65

70

75

ctc cac ggg gtc cca cag ggg gca ctt cta gag gac aac agg gaa cag 409

Leu His Gly Val Pro Gln Gly Ala Leu Leu Glu Asp Asn Arg Glu Gln

35

80

85

90

gaa tgt gaa atc atc agc ttt gct gag aca ggc ctc tcc acc atc aac 457

Glu Cys Glu Ile Ile Ser Phe Ala Glu Thr Gly Leu Ser Thr Ile Asn

40

95

100

105

110

cag act cgt ctt gat ttt cac ttc tcc tct gat aga act gct ggt gac 505

Gln Thr Arg Leu Asp Phe His Phe Ser Ser Asp Arg Thr Ala Gly Asp

45

115

120

125

- 30 -

```

agg gag gtc cag cag gcc agt ctc atg ttc ttt gtg cag ctc cct tcc      553

Arg Glu Val Gln Gln Ala Ser Leu Met Phe Phe Val Gln Leu Pro Ser
      130                      135                      140

5
aat acc act tgg acc ttg aaa gtg aga gtc ctt gtg ctg ggt cca cat      601

Asn Thr Thr Trp Thr Leu Lys Val Arg Val Leu Val Leu Gly Pro His
      145                      150                      155

10
aat acc aac ctc acc ttg gct act cag tac ctg ctg gag gtg gat gcc      649

Asn Thr Asn Leu Thr Leu Ala Thr Gln Tyr Leu Leu Glu Val Asp Ala
      160                      165                      170

15
agt ggc tgg cat caa ctc ccc cta ggg cct gaa gct caa gct gcc tgc      697

Ser Gly Trp His Gln Leu Pro Leu Gly Pro Glu Ala Gln Ala Ala Cys
      175                      180                      185                      190

20
agc cag ggg cac ctg acc ctg gag ctg gta ctt gaa ggc cag gta gcc      745

Ser Gln Gly His Leu Thr Leu Glu Leu Val Leu Glu Gly Gln Val Ala
      195                      200                      205

25
cag agc tca gtc atc ctg ggt gga gct gcc cat agg cct ttt gtg gca      793

Gln Ser Ser Val Ile Leu Gly Gly Ala Ala His Arg Pro Phe Val Ala
      210                      215                      220

30
gcc cgg gtg aga gtt ggg ggc aaa cac cag att cac cga cga ggc atc      841

Ala Arg Val Arg Val Gly Gly Lys His Gln Ile His Arg Arg Gly Ile
      225                      230                      235

35
gac tgc caa gga ggg tcc agg atg tgc tgt cga caa gag ttt ttt gtg      889

Asp Cys Gln Gly Gly Ser Arg Met Cys Cys Arg Gln Glu Phe Phe Val
      240                      245                      250

40
gac ttc cgt gag att ggc tgg cac gac tgg atc atc cag cct gag ggc      937

Asp Phe Arg Glu Ile Gly Trp His Asp Trp Ile Ile Gln Pro Glu Gly
      255                      260                      265                      270

45

```

- 31 -

tac gcc atg aac ttc tgc ata ggg cag tgc cca cta cac ata gca ggc 985

Tyr Ala Met Asn Phe Cys Ile Gly Gln Cys Pro Leu His Ile Ala Gly

275

280

285

5

atg cct ggt att gct gcc tcc ttt cac act gca gtg ctc aat ctt ctc 1033

Met Pro Gly Ile Ala Ala Ser Phe His Thr Ala Val Leu Asn Leu Leu

290

295

300

10

aag gcc aac aca gct gca ggc acc act gga ggg ggc tca nnn tgt gta 1081

Lys Ala Asn Thr Ala Ala Gly Thr Thr Gly Gly Gly Ser Xaa Cys Val

305

310

315

15

ccc acg gcc egg cgc ccc ctg tct ctg ctc tat tat gac agg gac agc 1129

Pro Thr Ala Arg Arg Pro Leu Ser Leu Leu Tyr Tyr Asp Arg Asp Ser

320

325

330

20

aac att gtc aag act gac ata cct gac atg gta gta gag gcc tgt ggg 1177

Asn Ile Val Lys Thr Asp Ile Pro Asp Met Val Val Glu Ala Cys Gly

335

340

345

350

25

tgc agt tagtctatgt gtggtatggg cagcccaagg ttgcatggga aaacacgccc 1233

Cys Ser

30 ctacagaagt gcacttctt gagaggagg aatgacctca ttctctgtcc agaattgtgga 1293

ctccctcttc ctgagcatct tatggaaatt accccacctt tgacttgaag aaaccttcat 1353

35

ctaaagcaag tcaactgtgcc atcttctga ccactaccct ctttcttagg gcatagtcca 1413

tcccgctagt ccatcccgct agccccactc cagggactca gacccatctc caaccatgag 1473

40

caatgccatc tggttcccag gcaaagacac ccttagctca cctttaatag accccataac 1533

- 32 -

ccactatgcc ttctgtcct ttctactcaa tggccccac tccaagatga gttgacacaa 1593

ccccctcccc caatttttgt ggatctccag agaggccctt ctttggattc accaaagttt 1653

5

agatcactgc tgccccaaaat agaggcttac ctacccccct ctttgttggtg agccccgtgc 1713

10

cttcttagtt gtccaggtga actactaaag ctctctttgc ataccttcat ccattttttg 1773

tccttctctg cctttctcta tgcccttaag gggtgacttg cctgagctct atcacctgag 1833

15

ctccccgcc ctctggcttc ctgctgaggt cagggcattt cttatccctg ttcctctct 1893

gtctaggtgt catggttctg tgtaactgtg gctattctgt gtccctacac tacctggcta 1953

20

ccccctcca tggccccagc tctgcctaca ttctgatttt tttttttttt ttttttttga 2013

25

aaagttaaaa attccttaat tttttattcc tgggtaccact accacaattt acagggcaat 2073

atacctgatg taatgaaaag aaaaagaaaa agacaaagct acaacagata aaagacctca 2133

30

ggaatgtaca tctaattgac actacattgc attaataat agctgcactt ttgcaaact 2193

gtggctatga cagtcctgaa caagaagggt ttctgttta agctgcagta acttttctga 2253

35

ctatggatca tcgttcctt 2272

40

<210> 4

<211> 352

<212> PRT

<213> Homo sapiens

45

- 33 -

<400> 4

	Met	Thr	Ser	Ser	Leu	Leu	Leu	Ala	Phe	Leu	Leu	Leu	Ala	Pro	Thr	Thr	
	1				5					10					15		
5	Val	Ala	Thr	Pro	Arg	Ala	Gly	Gly	Gln	Cys	Pro	Ala	Cys	Gly	Gly	Pro	
				20					25					30			
	Thr	Leu	Glu	Leu	Glu	Ser	Gln	Arg	Glu	Leu	Leu	Leu	Asp	Leu	Ala	Lys	
			35					40					45				
10	Arg	Ser	Ile	Leu	Asp	Lys	Leu	His	Leu	Thr	Gln	Arg	Pro	Thr	Leu	Asn	
		50					55					60					
	Arg	Pro	Val	Ser	Arg	Ala	Ala	Leu	Arg	Thr	Ala	Leu	Gln	His	Leu	His	
15		65				70				75						80	
	Gly	Val	Pro	Gln	Gly	Ala	Leu	Leu	Glu	Asp	Asn	Arg	Glu	Gln	Glu	Cys	
					85					90				95			
20	Glu	Ile	Ile	Ser	Phe	Ala	Glu	Thr	Gly	Leu	Ser	Thr	Ile	Asn	Gln	Thr	
				100					105					110			
	Arg	Leu	Asp	Phe	His	Phe	Ser	Ser	Asp	Arg	Thr	Ala	Gly	Asp	Arg	Glu	
			115					120					125				
25	Val	Gln	Gln	Ala	Ser	Leu	Met	Phe	Phe	Val	Gln	Leu	Pro	Ser	Asn	Thr	
		130					135					140					
	Thr	Trp	Thr	Leu	Lys	Val	Arg	Val	Leu	Val	Leu	Gly	Pro	His	Asn	Thr	
30		145				150					155					160	
	Asn	Leu	Thr	Leu	Ala	Thr	Gln	Tyr	Leu	Leu	Glu	Val	Asp	Ala	Ser	Gly	
				165					170					175			
35	Trp	His	Gln	Leu	Pro	Leu	Gly	Pro	Glu	Ala	Gln	Ala	Ala	Cys	Ser	Gln	
				180					185					190			
	Gly	His	Leu	Thr	Leu	Glu	Leu	Val	Leu	Glu	Gly	Gln	Val	Ala	Gln	Ser	
			195					200					205				
40	Ser	Val	Ile	Leu	Gly	Gly	Ala	Ala	His	Arg	Pro	Phe	Val	Ala	Ala	Arg	
		210					215					220					
	Val	Arg	Val	Gly	Gly	Lys	His	Gln	Ile	His	Arg	Arg	Gly	Ile	Asp	Cys	
45		225					230				235					240	

- 34 -

	Gln	Gly	Gly	Ser	Arg	Met	Cys	Cys	Arg	Gln	Glu	Phe	Phe	Val	Asp	Phe	
					245					250					255		
5	Arg	Glu	Ile	Gly	Trp	His	Asp	Trp	Ile	Ile	Gln	Pro	Glu	Gly	Tyr	Ala	
				260					265					270			
	Met	Asn	Phe	Cys	Ile	Gly	Gln	Cys	Pro	Leu	His	Ile	Ala	Gly	Met	Pro	
			275					280					285				
10	Gly	Ile	Ala	Ala	Ser	Phe	His	Thr	Ala	Val	Leu	Asn	Leu	Leu	Lys	Ala	
		290					295				300						
	Asn	Thr	Ala	Ala	Gly	Thr	Thr	Gly	Gly	Gly	Ser	Xaa	Cys	Val	Pro	Thr	
	305					310					315				320		
15	Ala	Arg	Arg	Pro	Leu	Ser	Leu	Leu	Tyr	Tyr	Asp	Arg	Asp	Ser	Asn	Ile	
				325					330					335			
	Val	Lys	Thr	Asp	Ile	Pro	Asp	Met	Val	Val	Glu	Ala	Cys	Gly	Cys	Ser	
20				340				345						350			

25

- 35 -

EPO - Munich
52

06. Aug. 1999

Claims

1. Protein selected from the members of the TGF- β superfamily,
characterized in that the protein is necessarily monomeric due to
substitution or deletion of a cysteine which is responsible for dimer
formation.
2. Protein according to claim 1,
characterized in that the protein is a mature protein or a
biologically active part or variant thereof.
3. Protein according to any one of the preceeding claims,
characterized in that the protein contains at least the 7 cysteine
region characteristic for the TGF- β protein superfamily.
4. Protein according to claim 3,
characterized in that it contains a consensus sequence according
to Formula I: $C(Y)_{25-29}CYYYC(Y)_{25-35}XC(Y)_{27-34}CYC$ or
Formula II: $C(Y)_{28}CYYYC(Y)_{30-32}XC(Y)_{31}CYC$, wherein C denotes
cysteine, Y denotes any amino acid and X denotes any amino acid
except cysteine.
5. Protein according to any one of claims 1 to 4,
characterized in that the protein is a morphogenetic protein.
6. Protein according to any one of the preceeding claims,
characterized in that the proteins belongs to the TGF- β , BMP, GDF,
activin or GDNF family.
7. Protein according to claim 6,
characterized in that the protein is MP52 (GDF5) or a biologically
active part or variant thereof.

- 36 -

8. Protein according to any one of the preceeding claims,
characterized in that it comprises the amino acid sequence
according to SEQ.ID.NO.2 or a part thereof.
- 5 9. Protein according to claim 6,
characterized in that the protein is MP121 or a biologically active
part or variant thereof.
- 10 10. Protein according to claim 9,
characterized in that it comprises the amino acid sequence
according to SEQ.ID.NO.4 or a part thereof.
- 15 11. Protein according to any one of claims 1 to 10,
characterized in that the cysteine residue is substituted by an
amino acid selected from the group of alanine, serine, threonine,
leucine, isoleucine, glycine and valine.
- 20 12. Protein according to any one of claims 1 to 11,
characterized in that it contains additional amino acids that
facilitate or mediate the transfer and localization of the protein in a
certain tissue.
- 25 13. Nucleic acid,
characterized in that it encodes a protein according to any one of
claims 1 to 12.
14. Nucleic acid according to claim 13,
characterized in that it is a DNA.
- 30 15. Nucleic acid according to claim 13 or 14,
characterized in that it contains a sequence as shown in
SEQ.ID.NO.1 or a fragment thereof.

- 37 -

16. Nucleic acid according to claim 13 or 14,
characterized in that it contains a sequence as shown in
SEQ.ID.NO.3 or a fragment thereof.
- 5 17. Nucleic acid according to any one of claims 13 to 16,
characterized in that it further contains suitable expression control
sequences facilitating and/or driving expression of the encoded
protein.
- 10 18. Expression vector,
characterized in that it contains a nucleic acid according to any
one of claims 13 to 17 in a suitable vector system.
- 15 19. Expression vector according to claim 18,
characterized in that the vector system is suitable for prokaryotic
expression.
- 20 20. Host cell,
characterized in that it contains a nucleic acid according to any
one of claims 13 to 17 or an expression vector according to claims
18 or 19 and upon expression of said nucleic acid or vector is able
to produce a monomeric protein according to any one of claims 1
to 12.
- 25 21. Host cell according to claim 20,
characterized in that it is a prokaryotic host cell.
22. Host cell according to claim 20,
characterized in that it is an embryonal cell.
- 30 23. Pharmaceutical composition,

- 38 -

characterized in that it contains at least one protein according to any one of claims 1 to 12 or at least one nucleic acid according to any one of claims 13 to 17, at least one expression vector according to any one of claims 18 or 19 or at least one host cell according to claim 20 or 22.

24. Pharmaceutical composition according to claim 23, characterized in that the protein and/or nucleic acid are contained in and/or on a biocompatible matrix material.

25. Pharmaceutical composition according to claim 24, characterized in that the matrix material is biodegradable.

26. Pharmaceutical composition according to claims 24 or 25, characterized in that the matrix material is itself osteogenically active.

27. Pharmaceutical composition according to any one of claims 23 to 26, for the prevention or therapy of diseases for which also the dimeric form of the protein would be indicated.

28. Pharmaceutical composition according to claim 27, for prevention or therapy of diseases associated with bone and/or cartilage damage or affecting bone and/or cartilage disease or situations in which cartilage and/or bone growth is desirable or for spinal fusion.

29. Pharmaceutical composition according to claim 27, for prevention or therapy of damaged or diseased tissue associated with connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue

- 39 -

including CNS tissue and neuropahtological situations, tissue of the sensory system, liver, pancreas, cardiac, blood vessel, renal, uterine and thyroid tissue, skin, mucous membranes, endothelium, epithelium, for promotion or induction of nerve growth, tissue
5 regeneration, angiogenesis, wound healing including ulcers, burns, injuries or skin grafts, induction of proliferation of progenitor cells or bone marrow cells, for maintenance of a state of proliferation or differentiation, for treatment or preservation of tissue or cells for organ or tissue transplantation, for integrity of gastrointestinal
10 lining, for treatment of disturbances in fertility, contraception or pregnancy.

30. Pharmaceutical composition according to any one of claims 23 to 29 for surgical local application, topical or systemic application.

31. Pharmaceutical compostion according to any one of claims 23 to 30
characterized in that it further contains pharmacologically
acceptable auxiliary substances.

32. Pharmaceutical composition according to any one of claims 30 or 31,
characterized in that the composition is injectable.

33. Pharmaceutical composition according to anyone of claims 30 to 32,
characterized in that it is contained in a vehicle that allows to
direct and release the composition to a determined site of action.

34. Pharmaceutical composition according to claim 33,
characterized in that the vehicle is selected from liposomes,
nanospheres, larger implantable containers and micropumps.

- 40 -

35. Use of a pharmaceutical composition according to any one of claims 23 to 34 for the prevention or treatment of any indications of the dimeric form of the protein.

5 bb/20780PEP 04.08.1999

- 41 -

EPO-Munich
52

06. Aug. 1999

Summary

5 The present invention is concerned with proteins selected from the members of the TGF- β superfamily, which are monomeric due to substitution or deletion of a cysteine which is responsible for dimer formation.

10 The invention is also concerned with nucleic acids, encoding such monomeric proteins, vectors or host cells containing the nucleic acids as well as with pharmaceutical compositions comprising the proteins or nucleic acids encoding the proteins. The pharmaceutical compositions can be applied advantageously for all indications for which the respective dimeric proteins are useful.

15

cl 19.07.1999

THIS PAGE BLANK (USPTO)

Fig. 1 A

EPO - Munich
52
06. Aug. 1999

Name: MP52, dimeric form

Formula	C ₁₁₈₄ H ₁₈₄₄ N ₃₃₀ O ₃₅₀ S ₂₂
Molecular weight	26994 Dalton
Amino acid composition	238 amino acids
Disulfide bond	7 bonds

Primary structure




Fig. 1 B

